Trial Profile
A Phase 2, Randomized Study of Proscavax, a PSA/IL-2/GM-CSF Vaccine, in Treatment-naive Patients With Clinically Localized Prostate Cancer Versus an Active Surveillance Strategy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs PSA-IL2-GM-CSF vaccine (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Theralink Technologies
- 19 Mar 2019 According to an OncBioMune Pharmaceuticals media release, the first open site is Beth Israel Deaconess Medical Center, a member of the Dana-Farberand Harvard Cancer Center and a teaching hospital of Harvard Medical School in Boston, MA.
- 19 Mar 2019 Status changed from not yet recruiting to recruiting, according to an OncBioMune Pharmaceuticals media release.
- 05 Mar 2019 Planned initiation date changed from 15 Aug 2018 to 28 Feb 2019.